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Abstract 
A hexanucleotide G4C2 repeat expansion in C9orf72 is the most common genetic cause of familial and sporadic 
cases of amyotrophic lateral sclerosis (ALS) and frontotemporal degeneration (FTD). The mutation is associated 
with a reduction of C9orf72 protein and accumulation of toxic RNA and dipeptide repeat aggregates. The ac-
cumulation of toxic RNA has been proposed to sequester RNA binding proteins thereby altering RNA pro-
cessing, consistent with previous transcriptome studies that have shown that the C9orf72 repeat expansion is 
linked to abundant splicing alterations and transcriptome changes. Here, we used a subcellular fractionation 
method and FACS to enrich for neuronal nuclei from C9orf72 repeat expanded post-mortem human ALS/FTD 
brains, and to remove neuronal nuclei with TDP-43 pathology which are observed in nearly all symptomatic 
C9orf72 repeat expanded cases. We show that the C9orf72 expansion is associated with relatively mild gene 
expression changes. Dysregulated genes were enriched for vesicle transport pathways, which is consistent with 
the known functions of C9orf72 protein. Further analysis suggests that the C9orf72 transcriptome is not driven 
by toxic RNA but is rather shaped by the depletion of pathologic TDP-43 nuclei and the loss of C9orf72 expres-
sion. These findings argue against RNA binding protein sequestration in neurons as a major contributor to 
C9orf72 mediated toxicity. 
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Introduction 
Amyotrophic lateral sclerosis (ALS) and fronto-
temporal degeneration (FTD) are fatal neuro-
degenerative diseases with overlapping clinical, 
pathologic and genetic features. ALS is a motor 
neuron disease that primarily affects the upper and 
lower motor neurons in the motor cortex and spi-
nal cord, respectively, whereas FTD affects the 
frontal and temporal lobes, thereby affecting cogni-
tion. The most common genetic cause of familial 
and sporadic cases of ALS and FTD was identified as 
a hexanucleotide G4C2 repeat expansion found in 
the gene C9orf72 (1, 2). The repeat expansion is 
found in the first intron of C9orf72 and can be tran-
scribed into pre-mRNA that contains the repeat. 
Original Paper 
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C9orf72 protein has been predicted to be a DENN 
Rab GTPase, and shown to be involved in vesicular 
trafficking (3-8). Three potential mechanisms of 
toxicity have been implicated in contributing to 
disease: haploinsufficiency due to reduction of 
C9orf72 protein; RNA foci and titration of RNA 
binding proteins; and dipeptide repeat protein ag-
gregates (reviewed in (9)). It is currently unclear 
which mechanism contributes most to toxicity. 
Gain of toxic function via RNA foci or dipep-
tide repeat proteins have been seen in cellular and 
animal models. Indeed, several RNA binding pro-
teins have been shown to colocalize with repeat 
containing RNA within RNA foci, suggesting that 
RNA binding protein titration may be mediating 
toxicity (10-12). Models overexpressing dipeptide 
repeat proteins and/or mutant RNA in both cell and 
animal systems have shown that the repeat expan-
sion and dipeptide proteins may confer toxicity via 
a variety of pathways including nucleolar stress, 
nucleocytoplasmic transport defects, heterochro-
matin abnormalities, and DNA damage (13-32). 
However, RNA foci and dipeptide repeat proteins 
do not correlate with neurodegeneration in human 
tissues and are not toxic in some experimental 
models (13-16, 33-36), raising questions about the 
relevance of whether these pathologies contribute 
to disease. 
The loss of C9orf72 protein has been substan-
tiated by the fact that C9orf72 expansion carriers 
have reduced C9orf72 mRNA and protein expres-
sion (1, 2, 37, 38). Thus, it is possible that loss of 
C9orf72 protein may contribute to disease. Howev-
er, knockout mouse models of C9orf72 do not show 
neuronal defects but, rather, exhibit an inflamma-
tory phenotype (39-41), although reduction of 
C9orf72 protein appears to exacerbate phenotypes 
in mice overexpressing mutant C9orf72 RNA (42). 
We have shown that a subset of C9orf72 expansion 
carriers exhibit C9orf72 promoter methylation, and 
this is associated with reduced C9orf72 associated 
pathology, later age at death in FTD patients, slow-
er rates of cerebral atrophy, and improved cogni-
tive ability (43-45). Moreover, the gnomAD human 
genetics database indicates that missense and loss 
of function C9orf72 mutations are tolerated and 
present in control populations (46). Consequently, 
the pathogenic role of the loss of C9orf72 protein 
in ALS/FTD is not entirely clear, and overall it re-
mains unclear which mechanism of toxicity con-
tributes most to disease. 
Efforts to better understand these mecha-
nisms include transcriptomic studies to determine 
whether RNA dysregulation can contribute to neu-
rodegeneration. Indeed, frontal cortical and motor 
neuron transcriptome analysis from ALS patients 
showed splicing changes, dysregulation of RNA 
processing pathways, and alternative polyadenyla-
tion in sporadic and C9orf72 expansion carriers (47-
49). More recently, a large transcriptome study of 
C9orf72 cases found changes in genes linked to 
vesicular transport (8). These studies are some-
times complicated by the complex cellular compo-
sition of brain tissue which includes neuronal sub-
types, oligodendrocytes, microglia, astrocytes, vas-
cular cells and other cell types. Laser capture mi-
crodissected tissue studies have been very useful 
(50) but are labor intensive and often are technical-
ly difficult due to relatively low yield and prepro-
cessing steps that can affect RNA quality (51). Sin-
gle cell RNA sequencing methods have recently 
addressed the issue of complex cellular mixtures 
within tissue but suffer from low coverage and data 
sparsity. 
We have previously reported the use of fluo-
rescence activated cell sorting (FACS) to identify 
transcriptome signatures in neuronal nuclei with-
out TDP-43 from post-mortem brain in ALS/FTD 
patients (52). Here, we have used the same method 
to determine the role of the C9orf72 repeat expan-
sion in post-mortem neurons from ALS/FTD pa-
tients. Compared to the profound transcriptome 
changes associated with the loss of normal nuclear 
TDP-43 protein (52), we found that the C9orf72 
mutation was associated with relatively mild gene 
expression changes and mild splicing changes. 
Moreover, the molecular signature is largely asso-
ciated with a loss of C9orf72 function, and not a 
gain of toxic RNA or dipeptide repeat aggregates. 
Materials and Methods 
Clinical and pathologic assessment 
Human autopsy tissue was obtained from the 
University of Pennsylvania Center for Neurodegen-
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erative Disease Research Brain Bank as described 
(53). Informed consent from next of kin was ob-
tained for every case. 
Isolation was performed exactly as previously 
described (52). Briefly, mid-frontal neocortex of all 
cases were dounce homogenized using pestil B 
(Kimble Chase) in 0.25M sucrose and adjusted to 
final molarity of 1.6M sucrose in TKM. The homog-
enate was spun on a 1.8M sucrose cushion on the 
Beckman Coulter XPN-80 ultracentrifuge at 40,000g 
for 40 minutes at 4°C (Beckman Coulter Inc, Indian-
apolis, IN, USA). Isolated nuclei were stained with 
Alexa Fluor 647 conjugated to 2089 (rabbit polyclo-
nal C-terminal anti-TDP-43 antibody, Center for 
Neurodegenerative Disease Research, University of 
Pennsylvania), Alexa Fluor 488 conjugated NeuN 
(EMD Millipore, Billerica, MA, USA), and DAPI (Invi-
trogen, Carlsbad, CA, USA). Alexa Fluor 647 was 
conjugated to 2089 according to the APEX Alexa 
Fluor 647 Antibody labeling kit protocol (Thermo 
Fisher Scientific, Waltham, MA, USA). Stained nu-
clei were sorted for single cells containing TDP-43 
and NeuN on the BD FACSAria II (BD Biosciences, 
San Jose, CA, USA) at 20 psi on 100µm nozzle. 
RNA Isolation and RNA-seq Library Generation 
Isolation and library generation was done as 
previously described (52). Briefly, RNA was extract-
ed using the standard protocol within the AllPrep 
DNA/RNA Micro kit (Qiagen, Germantown, MD, 
USA). RNA quality from sorted nuclear RNA was 
determined based on Bioanalyzer Picochip analysis 
(Agilent, Santa Clara, CA, USA). Isolated RNA was 
amplified, made into cDNA, sheared, and libraries 
were made. The library was quantified using the 
Qubit dsDNA kit (Invitrogen) and Kapa library quan-
tification kit (KapaBiosystems, Boston, MA). cDNA 
libraries were pooled, clustered on the cBot and 
subject to 100 or 125 base pairs paired end reads 
on the HiSeq 2000 or 2500 (Illumina, San Diego, CA, 
USA). 
Pre-processing, mapping and filtering of RNA-
seq data 
RNA-seq analysis was done as previously de-
scribed (52). Briefly, raw sequencing reads were 
demultiplexed through the UPenn Functional Ge-
nomics Core and analyzed for quality control using 
FastQC. Reads were mapped to the human genome 
(GRCh38, GENCODE release 22) using STAR and 
only uniquely mapping reads were selected for 
further analysis. Ribosomal and mitochondrial 
reads were removed and SAM files were converted 
to BAM files using samtools view and BAM files 
were sorted by coordinate with samtools sort. 
Creation of non-overlapping gene, exon and 
intron annotations 
Annotations were generated as previously de-
scribed (52). Briefly, annotations were based on the 
comprehensive gene annotation file of the GEN-
CODE Release 22 (GRCh38.p2). GTF file was loaded 
into R (Version 3.2.2; R Core Team (2015): “R: A 
Language and Environment for Statistical Compu-
ting”, R Foundation for Statistical Computing, Vien-
na, Austria) and converted into a TranscriptDb ob-
ject. From the TranscriptDb object, all annotated 
Ensembl genes and their exons were pulled out 
using exonsBy (by=”gene”) and Ensembl gene IDs 
were replaced by official gene symbols with bi-
omaRt (Version 2.26.1). Genes and introns were 
defined as previously described in the above chap-
ter. Regions shared by overlapping genes were 
removed to count reads that map to one gene or to 
genic elements (exon or intron) from one gene. 
Exons and introns annotations were used for sub-
sequent analyses in the R package DEXSeq 
(1.16.10). 
Differential gene and genic element expression 
analysis 
The genomic annotation used for read count-
ing was done as previously described (52). The 
mapped, filtered RNA sequencing reads were 
counted using a custom R script including the R 
packages Rsamtools (1.22.0), GenomicFeatures 
(1.22.8) and GenomicAlignments (1.6.3). Briefly, 
sorted BAM files were loaded into R (3.2.2) and the 
number of reads mapping to genes, exons or in-
trons, was computed. 
Genes were analyzed for differential expres-
sion using the R package DESeq2 (1.10.1). Analysis 
was used to determine differences between nuclei 
from both C9orf72 expansion cases and non-
diseased controls (option design=~experiment in 
DESeqDataSetFromMatrix tool where experiment is 
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the subject id). Sex effects were removed with the 
R package sva (3.18.0) according to the DESeq2 
vignette. Manual annotation of gene descriptions 
was performed using gene descriptions on NCBI. 
Differential genic element expression analysis 
was done using DEXSeq (1.16.10). Briefly, the sort-
ed BAM files were used to count the number of 
reads mapping to exons and introns using the exon 
and intron annotation generated above and com-
puted using findOverlaps and countSubjectHits. 
Reads mapping to exon-intron junctions were ex-
cluded. Sex was controlled for by including it in the 
linear model used in the analysis by adding the 
term “sex:exon”. The following linear models were 
used full model = ~sample + exon + sex:exon + ex-
periment:exon and reduced model = ~sample + 
exon + sex:exon + experiment:exon and reduced 
model = ~sample + exon + sex:exon, where sample 
is the sample id and experiment the subject id. In 
addition, dispersions were estimated using the tool 
estimateDispersions with option fitType=’local’. 
Changes in expression were significant if Bonferro-
ni-Hochberg multiple testing adjusted p-values 
were less than 0.05. 
Alternative splicing analysis 
Splicing analysis was performed as previously 
described (52). Briefly, all FASTQ files were 
trimmed to 100bp, aligned to GRCh38 using STAR; 
ribosomal and mitochondrial mapped reads were 
removed. SAM files were converted to sorted BAM 
files and rMATS.3.0.9 was run using default param-
eters with the following options (-t paired –len 100 
–c 0.05 – analysis U). Significant alternative splicing 
events were used if Bonferroni-Hochberg multiple 
testing adjusted p-values were less than 0.05. 
RNA binding protein CLIP analysis 
CLIP analysis was done as previously described 
(52) using published TDP-43 iCLIP data from SH-
SY5Y cells (54) and hnRNP A, A2B1, F, M, U CLIP 
data from HEK293 cells (55). Briefly, hg18 Bowtie 
files were converted to FASTQ files, and aligned to 
hg38. PIPECLIP was run using the python script. 
Using R, the “GenomicRanges” package with 
‘findOverlaps’ option was used to determine which 
bins had RNA binding protein sites. Chi-square 
analysis was done to determine whether there was 
a significant enrichment of bins with RNA binding 
protein sites within the significantly differentially 
used bins linked to the C9orf72 mutation. 
Principal Component Analysis 
Principal component analysis was done using 
the log transformed read count dataset in R with 
the ‘stats’ package and ‘prcomp’ function. The co-
ordinates were retrieved and used to plot principal 
component 2 (PC2) vs principal component 1. To 
determine the relationship between PC2 vs C9orf72 
expression, the coordinates of PC2 for each sample 
was plotted against the normalized C9orf72 expres-
sion calculated from DESeq2 from each sample. 
Pearson’s correlation was performed to determine 
the correlation between PC2 and C9orf72 expres-
sion. Gene ontology analysis of the top 1% of all 
genes that contribute to PC2 was done using 
Webgestaldt (56) with the overrepresentation en-
richment analysis using the ‘geneontology’ func-
tional database with a FDR corrected significance 
level < 0.05. 
Methylation Correlation 
Methylation levels for the C9orf72 promoter 
in patients were determined as previously de-
scribed (45). Briefly, genomic DNA from the cere-
bellum was extracted using the Qiagen DNeasy 
Blood and Tissue kit and subject to overnight diges-
tion with HhaI and HaeIII (double-digested) or just 
HaeIII (mock) alone. A small aliquot of DNA was 
amplified using primers flanking the HhaI cutsite 
within the C9orf72 promoter region using 2x 
FastStart SYBR Green Master (Roche) on the ABI 
StepOnePlus machine. The difference in cycles to 
threshold amplification between double and mock 
digested DNA was calculated as methylation values. 
Spearman’s correlation was calculated using gene 
counts for each gene and methylation values for 
each C9orf72 mutation case. R package ‘lsr’ with 
‘correlate’ function (with options corr.method
=”spearman” and p.adjust.method=”fdr”) using the 
Spearman’s correlation and FDR adjusted p-values 
was used. Only correlations from genes with HUGO 
gene symbols were calculated and plotted against 
gene fold change for each gene that was calculated 
by DESeq2. This was done using both significantly 
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differentially expressed genes linked to the C9orf72 
mutation (DESeq2 FDR p-value < 0.05) and ge-
nome-wide using all expressed genes. 
Results 
Fluorescence Activated Cell Sorting and RNA 
Sequencing of Sorted Neuronal Nuclei 
The C9orf72 mutation leads to TDP-43 pathol-
ogy which includes the formation of neuronal cyto-
plasmic inclusions and the loss of normal physiolog-
ic nuclear TDP-43 protein. We have previously 
shown that the loss of normal nuclear TDP-43 pro-
tein has large effects on the nuclear transcriptome 
(52). To determine whether the C9orf72 mutation 
leads to transcriptomic alterations independent of 
TDP-43 pathology, we isolated neuronal nuclei with 
intact TDP-43 expression. Mid-frontal neocortex 
from 7 post-mortem C9orf72 expansion carriers 
and 6 neurologically normal controls were used to 
isolate nuclei for transcriptome-wide analysis. The 
autopsy cohort characteristics can be found in Ta-
ble 1. Nuclei were immunostained for NeuN and 
TDP-43 and subjected to FAC sorting to isolate 
NeuN positive, TDP-43 positive nuclei from controls 
(circled, Fig 1A) and C9orf72 expansion cases (cir-
cled, Fig 1B). RNA from equal numbers of TDP-43 
positive neuronal nuclei (35,000-100,000) was ex-
tracted and amplified to generate barcoded cDNA 
libraries for 100 or 125bp paired end sequencing on 
the Illumina HiSeq 2000/2500. Sequences were 
mapped to the human genome (Gencode GRCh38) 
using STAR algorithms (version 2.2.4). There were 
1.8 billion reads of which 1.065 billion reads 
mapped uniquely between the 13 libraries, with an 
average of 90 million uniquely mapped reads per 
library. These reads were filtered to remove ribo-
somal and mitochondrial reads and the resulting 
reads were used for downstream analysis to evalu-
ate differential expression of genes, genic elements 
and alternative splicing. 
 
 
Table 1: Autopsy cohort characteristics. ALS = amyotrophic lateral sclerosis; FTLD = frontotemporal lobar degeneration with TDP-43 
inclusions; MND = motor neuron disease; NL = normal; PMI = post-mortem interval; RIN = RNA integrity number 
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Fig 1: C9orf72 repeat expansion contributes to relatively mild transcriptome changes. Flow cytometry plots of control (A) and C9orf72 
expansion cases (B) with TDP-43 positive neuronal nuclei circled as collected samples. (C) Principal component analysis using all ex-
pressed genes where shape denotes sex and color denotes condition. (D) Principal component 2 strongly correlates with C9orf72 ex-
pression (Pearson’s r = -0.8205; p=0.0006). (E) MA plot showing gene fold change as a function of mean normalized gene counts with 
red dots being significantly differentially expressed genes. (F) Pie chart distribution of all alternative splicing events between C9orf72 
expansion carriers and non-diseased controls. SE=skipped exons, MXE=mutually exclusive exons, RI=retained intron, A3SS=alternative 3’ 
splice site, A5SS=alternative 5’ splice site. 
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Functional transcriptomic alterations associated 
with the C9orf72 hexanucleotide repeat expan-
sion 
To verify that the variation within the dataset 
is linked to the mutation status, principal compo-
nent analysis (PCA) was performed using the read 
counts of the entire dataset (Fig 1C). Principal com-
ponent #1 (PC1) explained 21% of the variation 
whereas PC2 explained 19% of the variation (Fig 
1C). Based on the clustering of the dataset, sex 
explains the variation in PC1 while the C9orf72 
repeat expansion explains the variation in PC2. 
Indeed, PC2 strongly correlated with C9orf72 mRNA 
expression (Pearson’s r=-0.8205; p=0.0006), sug-
gesting that C9orf72 expression is the major under-
lying biological variable that contributes to the 
variation in PC2 (Fig 1D). To identify whether there 
were enriched pathways within the genes that con-
tribute most to PC2, gene ontology analysis was 
performed using the top 1% of all expressed genes 
(318 genes) that contribute to PC2. One pathway 
that is of interest is the cytoplasmic vesicle part or 
cytoplasmic vesicle membrane (Table 2) and is con-
sistent with the functional role of C9orf72 as a vesi-
cle trafficking protein and Rab GTPase (3, 5-7). 
 
Table 2: Gene ontology (GO) of genes related to top 1% of all 
genes that contribute to variation in PC2. 
 
Previous studies have found that the G4C2 RNA 
foci may colocalize with different RNA binding pro-
teins (RBPs), suggesting that sequestration of these 
RBPs can result in aberrant RNA processing (10-12). 
Differential gene expression analysis showed that 
there are 323 significantly differentially expressed 
genes with 202 upregulated and 121 downregulat-
ed genes linked to the C9orf72 mutation (Fig 1E, 
supplemental table 1). Similar to a previous tran-
scriptome analysis on C9orf72 expansion carriers 
on the frontal cortex, there were more upregulated 
genes than downregulated genes within the differ-
entially expressed genes (49). Notably, the number 
of differentially expressed genes linked the C9orf72 
repeat expansion was relatively mild compared to 
the massive transcriptome-wide alterations we 
previously described associated with TDP-43 pa-
thology in these same cases (5,576 significantly 
differentially expressed genes, described in (52)). 
Further annotation shows that these genes 
are generally involved in synaptic vesicle fusion or 
vesicle formation (Table 3). Additional genes relat-
ed to vesicle transport and endosomal trafficking 
are also dysregulated. Interestingly, nine out of 
these 11 genes are upregulated. Additional genes 
that were upregulated were involved in protein 
aggregation. DNAJB2 is almost exclusively ex-
pressed in neurons and has been shown to resolve 
TDP-43 aggregates by interacting with heat shock 
protein 70 (57). MGRN1 has been shown to confer 
cytoprotective effects in an ALS mouse model and 
can suppress chaperone associated misfolded pro-
tein aggregation and toxicity (58). Given that 
C9orf72 expansion cases exhibit protein aggregates 
in the form of dipeptide repeat protein and TDP-43 
inclusions, it is possible that these genes are up-
regulated in response to these aggregates. Lastly, 
there were also genes that are involved in DNA 
repair (FAAP20, FAM175A, FANCB, HMGN1) (59-62) 
and response to DNA damage (KDM4B and KIN) 
(63-65). Annotation of these genes reveal multiple 
themes relevant to C9orf72 including synaptic vesi-
cle formation, endosomal trafficking, chaperone 
associated protein aggregation, and DNA damage 
(Table 3). 
C9orf72 mutation is associated with mild splicing 
alterations 
Previous studies have shown that there are 
abundant alternative splicing changes that are 
linked to the C9orf72 mutation (49). The finding of 
RNA binding proteins that colocalize with RNA foci 
also support the idea that RNA binding protein 
sequestration and subsequent splicing alterations 
may contribute to mutant C9orf72 toxicity. To eval-
uate splicing changes associated with the C9orf72 
mutation, rMATS was used to align junction reads 
to annotated junctions from GRCh38 assembly. 
Within our dataset, there were a total of 112
Free Neuropathology 1:23 (2020) Elaine Y. Liu et al 





Table 3: Annotation of significantly differentially expressed genes with general terms relevant to C9orf72 mutation. FDR = false dis-
covery rate. 
 
events that were significantly alternatively spliced 
which included 84 skipped exons (SE), 9 mutually 
exclusive exons (MXE), 9 retained introns (RI), 8 
alternative 3’ splice sites (A3SS), and 2 alternative 
5’ splice site (A5SS) events (Fig 1F, supplemental 
table 2). These events affected 111 genes, of which 
only 3 were also significantly differentially ex-
pressed. Gene ontology analysis of 111 genes did 
not result in any significant enriched pathways. 
Therefore, we observed relatively mild splicing 
changes associated with the C9orf72 mutation. This 
may be due in part attributable to technical differ-
ences where the use of nuclear RNA in our study 
likely reduces sensitivity in terms of identifying 
splicing alterations. 
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Fig 2: The C9orf72 mutation is associated with differential usage of genic elements with RNA binding protein sites. (A) MA plot of 
DEXSeq differentially used genic elements with red being significantly differentially used elements. (B) Genic elements (5’ UTR, exon, 
intron, 3’ UTR) distribution associated with C9orf72 mutation and all expressed bins. (c) Differentially used elements that are bound by 
TDP-43 and hnRNP (χ2=5.617; p=0.0178). 
 
C9orf72 mutation is associated with differential-
ly used 3’ UTRs 
Altered RNA binding protein function has been 
proposed to contribute to C9orf72 toxicity. RNA 
binding proteins can bind to different genic ele-
ments including exons, introns and untranslated 
regions (UTR). If RBP activity is altered via titration 
of these proteins, it is possible the regions that may 
be bound by RBPs are also differentially expressed. 
Thus, DEXSeq was used to determine whether the 
presence of the repeat expansion resulted in dif-
ferential usage of genic elements. There were a 
total of 865 significantly differentially used ele-
ments linked to the repeat expansion affecting 791 
genes. Specifically, there were 610 significantly 
downregulated elements and 255 significantly up-
regulated elements (Fig 2A). When the elements 
were annotated as either 5’ UTR, exon, intron or 3’ 
UTR, there was a significant enrichment of differen-
tially used 3’ UTRs due to the C9orf72 mutation 
(13.35% vs 9.78%, χ2=12.50, p=0.0004) (Fig 2B). 
Given the role of RBPs in binding to 3’ UTRs, we 
hypothesized that the significantly differentially 
used elements were enriched for RBP binding sites. 
Thus, hnRNP binding sites, including that of TDP-43 
and other hnRNPs were identified using PIPE-CLIP 
algorithms applied to published data sets (54, 55, 
66). Indeed, there was an enrichment of differen-
tially used genic elements that contain TDP-43 and 
hnRNP binding sites (χ2=5.617, p=0.0178, Fig 2C). 
Thus, the C9orf72 expansion is associated with 
some differentially used genic elements with RBP 
binding sites. 
Transcriptomic signature due to depletion of 
TDP-43 pathologic nuclei 
Given that neurons with TDP-43 inclusions 
have died during the course of disease and our 
experimental design includes removal of neurons 
with TDP-43 pathology via FAC sorting before RNA 
sequencing, we next considered the possibility that 
the transcriptomic alterations associated with the 
C9orf72 mutation in this dataset would in part re-
flect the depletion of neurons vulnerable to TDP-43 
proteinopathy. Indeed, within the neocortex, TDP-
43 proteinopathy often preferentially affect neu-
rons in superficial cortical laminae (52, 67). As 
shown in Fig 3A, neurons with TDP-43 pathology 
including loss of nuclear TDP-43 (white) are deplet-
ed in C9orf72 expansion cases, while control brains 
have the normal complement of neurons (blue, Fig 
3B). As a result, we hypothesized that the depletion 
of diseased nuclei would contribute to the tran-
scriptomic alterations associated with the C9orf72 
mutation. Thus, we expected that common genes 
that were downregulated in C9orf72 expansion 
cases would be upregulated in nuclei without TDP-
43 and vice versa. Indeed, among the 118 common 
significant differentially expressed genes linked to 
TDP-43 loss (52) and the C9orf72 mutation, a ma-
jority of them were followed this pattern (Fig 3C, 
supplemental table 3). A linear regression analysis 
showed there was a negative correlation between 
the gene fold change linked to TDP-43 loss and the 
gene fold change linked to the C9orf72 mutation 
(Pearson’s r=-0.5708; p<0.0001). Furthermore, this 
relationship was extended transcriptome-wide 
where we observed a negative correlation in all 
commonly expressed genes derived from both data
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Fig 3: C9orf72 transcriptome is linked to depletion of TDP-43 pathologic nuclei. (A) In C9orf72 expansion cases, there are nuclei with 
TDP-43 (blue) and those without TDP-43 (white). For our transcriptome analysis, only nuclei with TDP-43 were collected (red box), 
thereby depleting nuclei without TDP-43. (B) In non-diseased controls, nuclei with TDP-43 were collected (red box). (C) Gene fold 
changes of genes that were common significant differentially expressed linked to TDP-43 loss and the C9orf72 mutation were plotted, 
showing that genes that were downregulated due to the C9orf72 mutation were upregulated due to TDP-43 loss, suggesting that deple-
tion of diseased nuclei (without TDP-43) can partially explain the transcriptomic changes observed in this dataset (Pearson’s r=-0.5708, 
p<0.0001). (D) Genome-wide gene fold changes that were expressed in both datasets linked to TDP-43 loss and C9orf72 mutation 
showed a similar pattern. 
 
sets (Fig 3D). For example, IGSF11 and PVRL3 ex-
pression, preferentially observed in superficial neo-
cortical layers and therefore increased in neuronal 
nuclei without TDP-43 protein (52), is significantly 
reduced in the C9orf72 transcriptome. Conversely, 
SYT6 and COL6A1 expression, preferentially ob-
served in deep neocortical layers and therefore 
decreased in neuronal nuclei without TDP-43 pro-
tein (52), is significantly increased in the C9orf72 
transcriptome. This suggested that depletion of the 
diseased nuclei in C9orf72 expansion cases may 
explain some of the transcriptomic alterations ob-
served in C9orf72 expansion cases. 
Global C9orf72 associated transcriptome chang-
es are linked to loss of function of the C9orf72 
protein 
Current hypotheses of C9orf72 toxicity include 
loss of C9orf72 protein or gain of toxic RNA foci and 
dipeptide repeat aggregates (9). While some tran-
scriptome changes which appear to be related to 
C9orf72 gain of toxic function (genes associated 
with proteostasis and DNA damage, dysregulation 
of transcripts with hnRNP 3’UTR binding sites), 
other changes appeared to be linked to the loss of 
C9orf72 protein (genes associated with vesicle 
membranes and endosomal trafficking). However, 
at a global transcriptome level, it was unclear 
whether the overall changes associated with the 
mutation reflect changes linked to a toxic gain of 
C9orf72 function or the loss of C9orf72 protein. 
C9orf72 RNA foci and dipeptide repeat protein 
aggregates are seen in C9orf72 repeat expansion 
carriers but absent in neurologically normal con-
trols. We have also demonstrated that within 
C9orf72 mutation carriers, C9orf72 promoter 
methylation is negatively correlated with the ac-
cumulation of RNA foci and dipeptide repeat pro-
tein aggregates in human brains (43-45). Based on
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Figure 4: C9orf72 transcriptome reflects the loss of C9orf72 function. (A) Theoretical analysis within C9orf72 mutation carriers, we 
predict that C9orf72 promoter methylation would negatively correlate with C9orf72 expression. (B) Theoretical analysis between 
C9orf72 mutation carriers and non-diseased controls, we predict that C9orf72 expression is downregulated compared to controls. This 
would be an example of a “concordant” gene that suggests this gene is linked to loss of C9orf72 protein. (C) Theoretical analysis within 
C9orf72 mutation carriers, we predict that C9orf72 promoter methylation would negative correlate with toxic RNA. (D) Theoretical 
analysis between C9orf72 expansion carriers and non-diseased controls, we predict that toxic RNA expression would be upregulated. 
This would be an example of a “discordant” gene that suggests this gene is linked to gain of toxic RNA. (E) Within the actual data, there 
was a negative relationship between C9orf72 expression and methylation (Pearson r=-0.6958, p=0.0825). (F) C9orf72 expression is 
downregulated in C9orf72 expansion carriers compared to controls (t-test, p=0.0003) as predicted in genes associated with the loss of 
C9orf72 protein. (G) Within C9orf72 mutation carriers, there was a strong correlation between the expression of SYP and C9orf72 meth-
ylation (Pearson r=0.8835, p=0.0083). (H) Between C9orf72 expansion carriers and controls, there was a significant upregulation of SYP 
in expansion carriers (t-test, p=0.03). (I) Using significantly differentially expressed genes, the methylation correlation within C9orf72 
mutation cases was plotted against gene fold change between normal C9orf72 mutation cases and controls. There were more concord-
ant genes than discordant genes, reflecting that the transcriptome was associated with loss of C9orf72 protein. (H) Genome wide analy-
sis of methylation correlation vs gene fold change shows the same trend. 
 
this, we developed a theoretical framework (Fig 4A-
D) wherein statistical analysis was performed with-
in C9orf72 expansion cases versus statistical analy-
sis between C9orf72 expansion cases and controls. 
As a theoretical example, using C9orf72 itself as a 
gene that contributes to the loss of C9orf72 pro-
tein, we predicted that within C9orf72 expansion 
carriers, methylation of the C9orf72 promoter 
would negatively correlate with C9orf72 expression 
(Fig 4A). Moreover, we predicted that between-
group analysis would show that C9orf72 expression 
is downregulated compared to controls (Fig 4B). 
This would be an example of a “concordant” gene 
which provides evidence that the altered gene ex-
pression is linked to the loss of C9orf72 protein. 
Conversely, using similar logic, if a gene contributes 
to the gain of toxic function such as the formation 
of toxic RNA, we would predict that within C9orf72 
expansion carriers, methylation of the C9orf72 
promoter would negatively correlate with toxic 
RNA (Fig 4C). However, between groups, this gene 
would be upregulated in C9orf72 expansion carriers 
compared to controls (Fig 4D). This would be an 
example of a “discordant” gene, which provides 
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evidence that altered expression of this gene is 
associated with a gain of toxic function. 
Using the actual data, a correlation analysis 
was performed comparing C9orf72 expression and 
methylation of the C9orf72 promoter within our 
C9orf72 expansion cohort (Pearson’s r=-0.6958; 
p=0.0825) (Fig 4E). Moreover, between-group anal-
ysis revealed that C9orf72 expression is downregu-
lated in C9orf72 expansion carriers compared to 
controls as expected (t-test, p=0.0003) (Fig 4F). 
Another example of a “concordant” gene is synap-
tophysin (SYP), a synaptic vesicle protein. The same 
correlation analysis was done which showed a posi-
tive correlation within C9orf72 expansion carriers 
(Pearson’s r=0.8835; p=0.0083), and an increase in 
expression in C9orf72 expansion carriers compared 
to controls (t-test, p=0.03) (Fig 4G-H, supplemental 
table 4). Thus, we are able to show that “concord-
ant” genes tend to reflect genes that may be relat-
ed to C9orf72 protein function. 
This analysis was extended to all significantly 
differentially expressed genes where the “within 
C9orf72 mutation cases” methylation correlation 
value was plotted as a function of “between 
C9orf72 cases and controls” gene fold change val-
ues (Fig 4I). Across all significantly differentially 
expressed genes, there were 267 genes found with-
in the concordant quadrants (blue circles) com-
pared to only 56 genes found in the discordant 
quadrants (red circles) (Fig 4G). Similar results were 
found when this analysis was further expanded 
transcriptome-wide, suggesting that the global 
transcriptome changes linked to the C9orf72 muta-
tion are associated with loss of C9orf72 protein (Fig 
4H). Many “concordant” genes were genes in-
volved in synaptic vesicle formation (i.e. clathrin 
light chain B, syntaphilin, synaptophysin) and vesi-
cle trafficking (i.e. multivesicular body subunit 12A, 
RAB40B, member RAS oncogene family). Genes 
labeled as “discordant” include genes related to 
inflammatory or apoptotic processes including tec 
protein tyrosine kinase, tyrosine kinase, and Ring 
finger protein 152. 
Thus two different factors appear to shape 
this global C9orf72 transcriptome dataset: (1) the 
depletion of neurons with TDP-43 pathology prior 
to RNA-sequencing and (2) the loss of C9orf72 func-
tion. To estimate the relative contributions of these 
two factors, a multivariate linear regression analy-
sis was performed wherein significant changes in 
gene expression associated with the C9orf72 muta-
tion were related to (1) the changes in gene ex-
pression we previously identified due to TDP-43 
pathology and (2) the loss of C9orf72 gene expres-
sion due to methylation of the C9orf72 promoter. 
Together, these two factors explained the majority 
of the variance in this dataset (R2=0.5138; 
βmethylation=0.838, p<2e-16; βTDP-43=-0.499, p<2e-16). 
Discussion 
Here we report that in using post-mortem 
neuronal nuclei without TDP-43 pathology from 
C9orf72 expansion carriers, we were able to identi-
fy transcriptome changes that link the C9orf72 mu-
tation with loss of C9orf72 function. We found that 
the top 1% of genes that contribute most to chang-
es in C9orf72 expression were involved in cyto-
plasmic vesicle trafficking. Significant gene expres-
sion changes were linked to the C9orf72 mutation 
and featured upregulated genes related to synaptic 
transmission and endosomal/lysosomal trafficking. 
Indeed, C9orf72 has been shown to be involved in 
endosomal or lysosomal trafficking and may be a 
Rab GTPase, and recent whole tissue transcriptome 
studies have linked the C9orf72 mutation to chang-
es in vesicular transport genes (3-8). Nine of the 11 
genes related to trafficking were upregulated, po-
tentially reflecting a compensatory mechanism to 
counteract the loss of C9orf72 and loss of this traf-
ficking related protein. 
Further analysis correlating methylation and 
gene expression changes confirmed that the tran-
scriptome changes are linked to loss of C9orf72 
expression. To parse the relative contributions of 
C9orf72 protein loss or gain of toxic RNA, a methyl-
ation correlation between methylation values and 
expression data was calculated. This correlation 
analysis indicated that the transcriptome observed 
in neuronal nuclei from C9orf72 expansion cases 
was driven in large part by the loss of C9orf72 pro-
tein as opposed to a toxic gain of function. In con-
trast, we observed minor splicing alterations and 
relatively subtle changes in terms of alterations in 
RNA binding protein function. Thus, the global al-
terations appear to be most reflective of a loss of 
C9orf72 function rather than toxic RNA mediated 
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effects. However, it should be noted that C9orf72 
methylation was used as a proxy for DPR and RNA 
foci levels. A more direct analysis of the effects of 
DPR or RNA foci would require specific isolation of 
DPR or RNA-foci containing neuronal nuclei which 
has not yet been possible using FAC sorting ap-
proaches. Additional future studies can also include 
comparisons between ALS/FTD cases with and 
without the C9orf72 mutation. 
Genes related to DNA repair either as a re-
sponse to DNA damage or important to employ 
DNA repair were also dysregulated. Interestingly, 
recent papers have shown that DNA damage is 
activated by the C9orf72 repeat expansion in both 
ALS patients and experimental models (23, 25, 26, 
30, 68). DNA damage has been a consistent feature 
among trinucleotide repeat expansion diseases and 
the dysregulation of DNA repair related genes is 
consistent with DNA damage contributing to neu-
rodegeneration (69). Furthermore, alterations in 
proteostasis either by failure to fold proteins 
properly or failure to degrade proteins likely con-
tribute to protein aggregation and are a common 
theme among all neurodegenerative diseases (70, 
71). Indeed, overexpressing proteostasis factors in 
animal and cell ALS models prevents protein accu-
mulation and aggregation (57, 72, 73), suggesting 
that altered proteostasis activity contributes to 
neurodegeneration. Thus, although the global tran-
scriptome appears to be driven by the loss of 
C9orf72 function, embedded within the C9orf72 
transcriptome are changes in gene expression, 
which may relate to the toxic functions of C9orf72. 
In comparing the data from previous tran-
scriptome analyses from C9orf72 expansion carri-
ers, several differences can be observed. Previous 
transcriptome analyses have identified pathways 
involved in inflammation and defense responses 
among dysregulated genes in the frontal cortices 
from C9orf72 expansion carriers (49). Within our 
dataset, we did not find enriched inflammatory 
pathways, which is likely due to the fact that only 
neurons were being sequenced. It is possible that 
because C9orf72 is expressed in microglia, C9orf72 
protein function may have a larger effect on micro-
glial populations (41). Given the evidence support-
ing that C9orf72 is involved inflammatory process-
es, further cell-specific analyses may prove benefi-
cial to better understanding the effects of mutant 
C9orf72 on non-neuronal cells in driving disease 
pathogenesis. 
Previous studies have found large numbers of 
splicing changes in C9orf72 expansion carriers and 
found motifs within these splicing changes that 
correspond to hnRNP H binding (49). However, we 
did not detect such large changes and instead 
found milder splicing changes with motifs that do 
not correspond to any known RNA foci colocaliza-
tion partners (data not shown). Current studies 
debated over the disease relevance of RNA foci as 
some animal models overexpressing the repeat 
induce RNA foci but do not show motor or cogni-
tive defects (13-16). The lack of splicing changes in 
our dataset does not support the model wherein 
neuronal toxicity is linked to the titration of RNA 
binding proteins within RNA foci. 
Overall, our findings argue against RNA toxici-
ty attributed to sequestration of RNA binding pro-
teins. Other disease-related pathways, such as pro-
tein aggregation and DNA repair, were observed in 
this dataset, supporting a potential role for dipep-
tide repeat protein aggregates and nuclear DNA 
damage in disease, consistent with experimental 
studies showing that overexpression of dipeptide 
repeat proteins are toxic both in cells and in animal 
models (13-32). While the transcriptome appeared 
to be shaped in large part by the loss of C9orf72 
function, it is unclear whether the loss of C9orf72 
function contributes to disease and thus under-
standing whether these changes are functionally 
linked to disease pathogenesis requires additional 
experimental studies and validation. Finally, our 
analysis highlights the complexities associated with 
molecular studies of post-mortem human tissue 
wherein issues related to cell identity, experimental 
design, and admixtures of both gain and loss of 
function effects can be seen concurrently. 
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